CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2

Marika Sciandra, Maria Teresa Marino, Maria Cristina Manara, Clara Guerzoni, Maria Grano, Angela Oranger, Enrico Lucarelli, Pier Luigi Lollini, Barbara Dozza, Loredana Pratelli, Maria Flavia Di Renzo, Mario Paolo Colombo, Piero Picci, Katia Scotlandi

Research output: Contribution to journalArticle

Abstract

Differentiation therapy is an attractive treatment for osteosarcoma (OS). CD99 is a cell surface molecule expressed in mesenchymal stem cells and osteoblasts that is maintained during osteoblast differentiation while lost in OS. Herein, we show that whenever OS cells regain CD99, they become prone to reactivate the terminal differentiation program. In differentiating conditions, CD99-transfected OS cells express osteocyte markers, halt proliferation, and largely die by apoptosis, resembling the fate of mature osteoblasts. CD99 induces ERK activation, increasing its membrane-bound/cytoplasmic form rather than affecting its nuclear localization. Through cytoplasmic ERK, CD99 promotes activity of the main osteogenic transcriptional factors AP1 and RUNX2, which in turn enhance osteocalcin and p21WAF1/CIP1, leading to G 0/G1 arrest. These data underscore the alternative positions of active ERK into distinct subcellular compartments as key events for determining OS fate.

Original languageEnglish
Pages (from-to)1295-1309
Number of pages15
JournalJournal of Bone and Mineral Research
Volume29
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Osteosarcoma
Cell Differentiation
Osteoblasts
Osteocytes
Osteocalcin
Mesenchymal Stromal Cells
Cell Membrane
Apoptosis

Keywords

  • CD99
  • mapk signaling
  • osteoblast differentiation
  • osteosarcoma
  • RUNX2

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. / Sciandra, Marika; Marino, Maria Teresa; Manara, Maria Cristina; Guerzoni, Clara; Grano, Maria; Oranger, Angela; Lucarelli, Enrico; Lollini, Pier Luigi; Dozza, Barbara; Pratelli, Loredana; Di Renzo, Maria Flavia; Colombo, Mario Paolo; Picci, Piero; Scotlandi, Katia.

In: Journal of Bone and Mineral Research, Vol. 29, No. 5, 2014, p. 1295-1309.

Research output: Contribution to journalArticle

Sciandra, Marika ; Marino, Maria Teresa ; Manara, Maria Cristina ; Guerzoni, Clara ; Grano, Maria ; Oranger, Angela ; Lucarelli, Enrico ; Lollini, Pier Luigi ; Dozza, Barbara ; Pratelli, Loredana ; Di Renzo, Maria Flavia ; Colombo, Mario Paolo ; Picci, Piero ; Scotlandi, Katia. / CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. In: Journal of Bone and Mineral Research. 2014 ; Vol. 29, No. 5. pp. 1295-1309.
@article{510effea375a4a5a91e94227c9e09af3,
title = "CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2",
abstract = "Differentiation therapy is an attractive treatment for osteosarcoma (OS). CD99 is a cell surface molecule expressed in mesenchymal stem cells and osteoblasts that is maintained during osteoblast differentiation while lost in OS. Herein, we show that whenever OS cells regain CD99, they become prone to reactivate the terminal differentiation program. In differentiating conditions, CD99-transfected OS cells express osteocyte markers, halt proliferation, and largely die by apoptosis, resembling the fate of mature osteoblasts. CD99 induces ERK activation, increasing its membrane-bound/cytoplasmic form rather than affecting its nuclear localization. Through cytoplasmic ERK, CD99 promotes activity of the main osteogenic transcriptional factors AP1 and RUNX2, which in turn enhance osteocalcin and p21WAF1/CIP1, leading to G 0/G1 arrest. These data underscore the alternative positions of active ERK into distinct subcellular compartments as key events for determining OS fate.",
keywords = "CD99, mapk signaling, osteoblast differentiation, osteosarcoma, RUNX2",
author = "Marika Sciandra and Marino, {Maria Teresa} and Manara, {Maria Cristina} and Clara Guerzoni and Maria Grano and Angela Oranger and Enrico Lucarelli and Lollini, {Pier Luigi} and Barbara Dozza and Loredana Pratelli and {Di Renzo}, {Maria Flavia} and Colombo, {Mario Paolo} and Piero Picci and Katia Scotlandi",
year = "2014",
doi = "10.1002/jbmr.2141",
language = "English",
volume = "29",
pages = "1295--1309",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2

AU - Sciandra, Marika

AU - Marino, Maria Teresa

AU - Manara, Maria Cristina

AU - Guerzoni, Clara

AU - Grano, Maria

AU - Oranger, Angela

AU - Lucarelli, Enrico

AU - Lollini, Pier Luigi

AU - Dozza, Barbara

AU - Pratelli, Loredana

AU - Di Renzo, Maria Flavia

AU - Colombo, Mario Paolo

AU - Picci, Piero

AU - Scotlandi, Katia

PY - 2014

Y1 - 2014

N2 - Differentiation therapy is an attractive treatment for osteosarcoma (OS). CD99 is a cell surface molecule expressed in mesenchymal stem cells and osteoblasts that is maintained during osteoblast differentiation while lost in OS. Herein, we show that whenever OS cells regain CD99, they become prone to reactivate the terminal differentiation program. In differentiating conditions, CD99-transfected OS cells express osteocyte markers, halt proliferation, and largely die by apoptosis, resembling the fate of mature osteoblasts. CD99 induces ERK activation, increasing its membrane-bound/cytoplasmic form rather than affecting its nuclear localization. Through cytoplasmic ERK, CD99 promotes activity of the main osteogenic transcriptional factors AP1 and RUNX2, which in turn enhance osteocalcin and p21WAF1/CIP1, leading to G 0/G1 arrest. These data underscore the alternative positions of active ERK into distinct subcellular compartments as key events for determining OS fate.

AB - Differentiation therapy is an attractive treatment for osteosarcoma (OS). CD99 is a cell surface molecule expressed in mesenchymal stem cells and osteoblasts that is maintained during osteoblast differentiation while lost in OS. Herein, we show that whenever OS cells regain CD99, they become prone to reactivate the terminal differentiation program. In differentiating conditions, CD99-transfected OS cells express osteocyte markers, halt proliferation, and largely die by apoptosis, resembling the fate of mature osteoblasts. CD99 induces ERK activation, increasing its membrane-bound/cytoplasmic form rather than affecting its nuclear localization. Through cytoplasmic ERK, CD99 promotes activity of the main osteogenic transcriptional factors AP1 and RUNX2, which in turn enhance osteocalcin and p21WAF1/CIP1, leading to G 0/G1 arrest. These data underscore the alternative positions of active ERK into distinct subcellular compartments as key events for determining OS fate.

KW - CD99

KW - mapk signaling

KW - osteoblast differentiation

KW - osteosarcoma

KW - RUNX2

UR - http://www.scopus.com/inward/record.url?scp=84899092275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899092275&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2141

DO - 10.1002/jbmr.2141

M3 - Article

C2 - 24677094

AN - SCOPUS:84899092275

VL - 29

SP - 1295

EP - 1309

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 5

ER -